Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CEDILANID-D vs SENSIPAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Digitalis glycoside; inhibits Na+/K+-ATPase, increasing intracellular calcium and cardiac contractility.
Calcimimetic agent that allosterically modulates the calcium-sensing receptor (Ca SR) on parathyroid chief cells, increasing its sensitivity to extracellular calcium, thereby reducing parathyroid hormone (PTH) secretion.
Heart failure,Atrial fibrillation,Atrial flutter
Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis,Hypercalcemia in patients with parathyroid carcinoma,Severe hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy
0.05 to 0.2 mg intravenously or intramuscularly, administered slowly over 5 minutes; initial dose 0.15 to 0.2 mg, then 0.1 to 0.15 mg every 30 minutes up to a total of 0.4 mg. Oral: 0.05 to 0.2 mg daily for maintenance.
30 mg orally once daily, titrated every 2-4 weeks to a maximum of 180 mg once daily to achieve target i PTH reduction.
Terminal elimination half-life is 36-48 hours in patients with normal renal function; prolonged to >100 hours in severe renal impairment, requiring dose adjustment.
The terminal elimination half-life of cinacalcet is approximately 30 to 40 hours in patients with normal renal function, supporting once-daily dosing. Steady-state concentrations are achieved within 7 days.
Hepatic (minor); primarily renally excreted unchanged.
Hepatic via CYP3A4, CYP2D6, CYP1A2; major metabolites are inactive.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 30-40%, with enterohepatic circulation present.
Renal excretion of unchanged drug and metabolites accounts for approximately 84% of the administered dose; fecal excretion accounts for approximately 11%. The primary metabolic pathway is CYP3A4-mediated oxidation, followed by glucuronidation.
25-30% bound to plasma albumin.
Cinacalcet is approximately 93 to 97% bound to plasma proteins, primarily to albumin and alpha-1-acid glycoprotein.
6-10 L/kg; large Vd indicates extensive tissue distribution and high cardiac tissue affinity.
The volume of distribution is approximately 1000 L (about 14 L/kg in a 70 kg individual), indicating extensive tissue distribution.
Oral: 70-80%; IV: 100%.
Oral bioavailability is approximately 20 to 25% due to first-pass metabolism; administration with food increases bioavailability by approximately 50% compared to fasting.
GFR <50 m L/min: reduce dose by 50% or extend dosing interval to every 36-48 hours. GFR <10 m L/min: avoid use or reduce dose by 75%.
No dose adjustment required for mild to moderate renal impairment (Cr Cl >= 30 m L/min). Not recommended for patients with severe renal impairment (Cr Cl < 30 m L/min) due to lack of data.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 25-50%. Child-Pugh Class C: avoid use or reduce dose by 75%.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh Class A or B). Use with caution in severe hepatic impairment (Child-Pugh Class C) with no specific dose recommendations.
Digitalizing dose: 0.01-0.02 mg/kg IV or IM, given in divided doses over 24 hours. Maintenance: 10-20% of digitalizing dose daily. Not recommended for neonates due to prolonged half-life.
Safety and effectiveness in pediatric patients have not been established.
Reduce dose by 25-50% due to decreased renal function and increased sensitivity. Monitor serum levels and renal function closely.
No specific dose adjustment; dosing should be based on renal function. Elderly patients may have decreased renal function; monitor serum calcium and i PTH levels closely.
Can cause potentially fatal arrhythmias; use only when clearly indicated and monitor serum levels.
None.
Narrow therapeutic index; toxicity risk increased with hypokalemia, hypomagnesemia, hypercalcemia, renal impairment; monitor ECG and drug levels.
Hypocalcemia: monitor serum calcium, especially during initiation and dose titration,Seizures: risk due to hypocalcemia,QT prolongation: caution in patients with history of QT interval prolongation or on concurrent QT-prolonging drugs,Hypotension: possible during dialysis use,Adynamic bone disease: potential with oversuppression of PTH
Ventricular fibrillation, digitalis toxicity, hypersensitivity, AV block (unless pacemaker present), Wolff-Parkinson-White syndrome.
Hypocalcemia (serum calcium < 8.4 mg/d L)
Avoid licorice, which can cause hypokalemia. Maintain consistent intake of potassium-rich foods (bananas, oranges) to avoid fluctuations. No known significant food interactions beyond electrolyte effects.
SENSIPAR should be taken with food or shortly after a meal to enhance absorption. No specific foods are contraindicated, but avoid high-calcium meals immediately before or after dosing as they may reduce absorption. Grapefruit and grapefruit juice may increase cinacalcet levels; avoid concurrent use.
Pregnancy Category C. First trimester: No adequate human studies; animal studies show fetal risk. Second/third trimester: Risk of fetal bradycardia, cardiac glycoside toxicity; avoids if possible.
First trimester: Limited human data; animal studies show fetal harm at high doses (reduced fetal weight, skeletal variations). Second/third trimester: No adequate human studies; potential fetal/neonatal hypocalcemia due to maternal calcium-sensing receptor modulation. Risk cannot be excluded.
Deslanoside is excreted in breast milk; estimated infant dose 0.1-0.5% of maternal weight-adjusted dose; M/P ratio not well defined. Monitor infant for bradycardia, feeding difficulties; benefit likely outweighs risk.
No human data on excretion in breast milk; M/P ratio unknown. Potential for serious adverse reactions (e.g., hypocalcemia) in nursing infants; decision to discontinue breastfeeding or drug based on importance of drug to mother.
Increased renal clearance in pregnancy may require higher doses; monitor serum drug levels and adjust accordingly. Reduced dosing in third trimester may be needed due to volume expansion.
No specific dose adjustment guidelines; pharmacokinetics in pregnancy unknown. Monitor serum calcium frequently and adjust dose to maintain target calcium levels. Consider that volume of distribution and clearance may increase, potentially requiring higher doses.
Cedilanid-D (deslanoside) is a rapidly acting parenteral digitalis glycoside. Use with extreme caution in renal impairment due to reduced clearance. Monitor serum potassium and magnesium; hypokalemia and hypomagnesemia potentiate toxicity. Administer slow IV push over 5 minutes to avoid arrhythmias. Therapeutic drug monitoring less common due to short half-life of 33 hours. Contraindicated in ventricular tachycardia and AV block (unless due to atrial fibrillation).
SENSIPAR (cinacalcet) is a calcimimetic used for secondary hyperparathyroidism in CKD on dialysis and for hypercalcemia in parathyroid carcinoma. Monitor serum calcium closely; hypocalcemia is a common adverse effect. Do not initiate if serum calcium is below the lower limit of normal. Administer with food or shortly after a meal to increase absorption. Dose adjustments may be needed with moderate to severe hepatic impairment.
Take exactly as prescribed; do not double doses.,Report symptoms of toxicity: nausea, vomiting, visual disturbances (yellow-green halos), irregular heartbeat.,Avoid over-the-counter medications without consulting doctor.,Maintain consistent potassium intake; avoid high-potassium foods or supplements unless advised.,Monitor daily weight and report rapid weight gain or edema.
Take this medication with food or right after a meal.,Do not split, crush, or chew tablets; swallow whole.,Report symptoms of low calcium: muscle cramps, numbness, tingling, or seizures.,Keep all lab appointments for calcium and PTH monitoring.,Avoid taking with other medications without consulting your doctor; some may interact.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CEDILANID-D vs SENSIPAR, answered by our medical review team.
CEDILANID-D is a Cardiac Glycoside that works by Digitalis glycoside; inhibits Na+/K+-ATPase, increasing intracellular calcium and cardiac contractility.. SENSIPAR is a Calcimimetic that works by Calcimimetic agent that allosterically modulates the calcium-sensing receptor (Ca SR) on parathyroid chief cells, increasing its sensitivity to extracellular calcium, thereby reducing parathyroid hormone (PTH) secretion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CEDILANID-D and SENSIPAR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CEDILANID-D is: 0.05 to 0.2 mg intravenously or intramuscularly, administered slowly over 5 minutes; initial dose 0.15 to 0.2 mg, then 0.1 to 0.15 mg every 30 minutes up to a total of 0.4 mg. Oral: 0.05 to 0.2 mg daily for maintenance.. The standard adult dose of SENSIPAR is: 30 mg orally once daily, titrated every 2-4 weeks to a maximum of 180 mg once daily to achieve target i PTH reduction.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CEDILANID-D and SENSIPAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CEDILANID-D is classified as Category C. Pregnancy Category C. First trimester: No adequate human studies; animal studies show fetal risk. Second/third trimester: Risk of fetal bradycardia, cardiac glycoside toxicity; avo. SENSIPAR is classified as Category C. First trimester: Limited human data; animal studies show fetal harm at high doses (reduced fetal weight, skeletal variations). Second/third trimester: No adequate human studies; po. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.